Literature DB >> 28330785

The interplay between Angiotensin II, TLR4 and hypertension.

Vinicia Campana Biancardi1, Gisele Facholi Bomfim2, Wagner Luis Reis3, Sarah Al-Gassimi4, Kenia Pedrosa Nunes5.   

Abstract

Hypertension is a multifactorial disease. Although a number of different underlying mechanisms have been learned from the various experimental models of the disease, hypertension still poses challenges for treatment. Angiotensin II plays an unquestionable role in blood pressure regulation acting through central and peripheral mechanisms. During hypertension, dysregulation of the Renin-Angiotensin System is associated with increased expression of pro-inflammatory cytokines and reactive oxygen species causing kidney damage, endothelial dysfunction, and increase in sympathetic activity, among other damages, eventually leading to decline in organ function. Recent studies have shown that these effects involve both the innate and the adaptive immune response. The contribution of adaptive immune responses involving different lymphocyte populations in various models of hypertension has been extensively studied. However, the involvement of the innate immunity mediating inflammation in hypertension is still not well understood. The innate and adaptive immune systems intimately interact with one another and are essential to an effectively functioning of the immune response; hence, the importance of a better understanding of the underlying mechanisms mediating innate immune system during hypertension. In this review, we aim to discuss mechanisms linking Angiotensin II and the innate immune system, in the pathogenesis of hypertension. The newest research investigating Angiotensin II triggering toll like receptor 4 activation in the kidney, vasculature and central nervous system contributing to hypertension will be discussed. Understanding the role of the innate immune system in the development of hypertension may bring to light new insights necessary to improve hypertension management.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiotensin II; Central nervous system; Hypertension; Innate immune system; Kidney; Vasculature

Mesh:

Substances:

Year:  2017        PMID: 28330785     DOI: 10.1016/j.phrs.2017.03.017

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  39 in total

1.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

Review 2.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

Review 3.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

Review 4.  Angiotensin-converting enzyme in innate and adaptive immunity.

Authors:  Kenneth E Bernstein; Zakir Khan; Jorge F Giani; Duo-Yao Cao; Ellen A Bernstein; Xiao Z Shen
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

Review 5.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 6.  Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?

Authors:  Kenia Pedrosa Nunes; Amanda Almeida de Oliveira; Francesca Elisabeth Mowry; Vinicia Campana Biancardi
Journal:  Br J Pharmacol       Date:  2018-08-09       Impact factor: 8.739

7.  Inhibition of STAT3 activation mediated by toll-like receptor 4 attenuates angiotensin II-induced renal fibrosis and dysfunction.

Authors:  Zheng Xu; Chunpeng Zou; Weihui Yu; Sujing Xu; Lan Huang; Zia Khan; Jingying Wang; Guang Liang; Yi Wang
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 8.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

9.  Pro-inflammatory cytokines in the paraventricular nucleus mediate the adipose afferent reflex in rats.

Authors:  Peng Lu; Li-Wen Liang; Ai-Li Xu; Ye-Ying Sun; Shu-Jun Jiang; Zhen Shi
Journal:  Pflugers Arch       Date:  2020-02-21       Impact factor: 3.657

Review 10.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.